Cargando…

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates

The COVID-19 pandemic has exemplified that rigorous evaluation in large animal models is key for translation from promising in vitro results to successful clinical implementation. Among the drugs that have been largely tested in clinical trials but failed so far to bring clear evidence of clinical e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marlin, Romain, Desjardins, Delphine, Contreras, Vanessa, Lingas, Guillaume, Solas, Caroline, Roques, Pierre, Naninck, Thibaut, Pascal, Quentin, Behillil, Sylvie, Maisonnasse, Pauline, Lemaitre, Julien, Kahlaoui, Nidhal, Delache, Benoit, Pizzorno, Andrés, Nougairede, Antoine, Ludot, Camille, Terrier, Olivier, Dereuddre-Bosquet, Nathalie, Relouzat, Francis, Chapon, Catherine, Ho Tsong Fang, Raphael, van der Werf, Sylvie, Rosa Calatrava, Manuel, Malvy, Denis, de Lamballerie, Xavier, Guedj, Jeremie, Le Grand, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427089/ https://www.ncbi.nlm.nih.gov/pubmed/36042198 http://dx.doi.org/10.1038/s41467-022-32565-w

Ejemplares similares

SARS-CoV-2 viral dynamics in non-human primates
por: Gonçalves, Antonio, et al.
Publicado: (2021)

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2021)

Computed tomography and [(18)F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates
por: Naninck, Thibaut, et al.
Publicado: (2022)

Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates
por: Marc, Aurélien, et al.
Publicado: (2023)

Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection
por: Alexandre, Marie, et al.
Publicado: (2022)

Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model
por: Hérate, Cécile, et al.
Publicado: (2023)

Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin
por: Lingas, Guillaume, et al.
Publicado: (2021)

Favipiravir Inhibits Mayaro Virus Infection in Mice
por: Bengue, Michèle, et al.
Publicado: (2021)

Comparison of Aerosol Deposition Between a Cynomolgus Macaque and a 3D Printed Cast Model of the Animal
por: Creppy, Justina, et al.
Publicado: (2023)

Impact of a PMMA tube on performances of a Vereos PET/CT system adapted for BSL-3 environment according to the NEMA NU2-2012 standard
por: Kahlaoui, Nidhal, et al.
Publicado: (2022)

Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques
por: Zabaleta, Nerea, et al.
Publicado: (2022)

Non-human primate models of human respiratory infections
por: Lemaitre, Julien, et al.
Publicado: (2021)

Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load
por: Gonçalves, Antonio, et al.
Publicado: (2020)

Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
por: Eloy, Philippine, et al.
Publicado: (2021)

Antiretroviral Treatment Start-Time during Primary SIV(mac) Infection in Macaques Exerts a Different Impact on Early Viral Replication and Dissemination
por: Sellier, Pierre, et al.
Publicado: (2010)

The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers
por: Malvy, Denis, et al.
Publicado: (2020)

Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials
por: Madelain, Vincent, et al.
Publicado: (2020)

Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques
por: Marlin, Romain, et al.
Publicado: (2021)

Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy
por: Pizzorno, Andrés, et al.
Publicado: (2019)

A Case Study to Dissect Immunity to SARS-CoV-2 in a Neonate Nonhuman Primate Model
por: Fovet, Claire-Maëlle, et al.
Publicado: (2022)

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
por: Nguyen, Thi Huyen Tram, et al.
Publicado: (2017)

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques
por: Guedj, Jérémie, et al.
Publicado: (2018)

Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection
por: Sulbaran, Guidenn, et al.
Publicado: (2022)

A novel adjuvant formulation induces robust Th1/Th17 memory and mucosal recall responses in Non-Human Primates
por: Woodworth, Joshua S, et al.
Publicado: (2023)

Detection of SARS-CoV-2 in subcutaneous fat but not visceral fat, and the disruption of fat lymphocyte homeostasis in both fat tissues in the macaque
por: Olivo, Anaëlle, et al.
Publicado: (2022)

Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates
por: Reynard, Stéphanie, et al.
Publicado: (2021)

Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2
por: Touret, Franck, et al.
Publicado: (2021)

Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia
por: Nicolas de Lamballerie, Claire, et al.
Publicado: (2019)

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
por: Maisonnasse, Pauline, et al.
Publicado: (2021)

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
por: Maisonnasse, P, et al.
Publicado: (2021)

In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses
por: Checkmahomed, Liva, et al.
Publicado: (2020)

Transcriptional Profiling of Immune and Inflammatory Responses in the Context of SARS-CoV-2 Fungal Superinfection in a Human Airway Epithelial Model
por: Nicolas de Lamballerie, Claire, et al.
Publicado: (2020)

Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates
por: Hermet, Paule, et al.
Publicado: (2023)

Efficacy and Safety of Favipiravir in Treating COVID-19 Patients: A Meta-Analysis of Randomized Control Trials
por: Batool, Saima, et al.
Publicado: (2023)

SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota
por: Sokol, Harry, et al.
Publicado: (2021)

Innate and Adaptive Anti-SIV Responses in Macaque Semen: Implications for Infectivity and Risk of Transmission
por: Suphaphiphat, Karunasinee, et al.
Publicado: (2020)

Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model
por: Cochin, Maxime, et al.
Publicado: (2022)

Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy
por: Thiberville, Simon-Djamel, et al.
Publicado: (2013)

In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2
por: Pizzorno, Andrés, et al.
Publicado: (2020)

410: Pseudomonas aeruginosa modulates SARS-CoV-2 infectivity in CF airway epithelial cells by increasing expression of the host protease TMPRSS2
por: Ruffin, M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k0hlbgh90rkob43dbpadi7hcen